Lexology (registration) Teva was a large, successful supplier of generic products and it had, in the past, shown that it was demonstrably prepared to launch products without notice and with the risk of patent infringement (e.g. with the launch of atorvastatin in June 2011 ...
MedPage Today ... to help regulate the products that will make their way to the American drugstores. Taylor noted cases of counterfeit or adulterated products entering the U.S., including atorvastatin (Lipitor) in 2003, heparin in 2008, and most recently bevacizumab ...
Dallas Morning News (blog) In the July 2013 edition of Circulation: Cardiovascular Quality and Outcomes, 135 previous studies, which included 250,000 people taking stati...
